Teva Canada Ltd.

Teva Canada Ltd. is the Canadian operating subsidiary of Teva Pharmaceutical Industries Ltd., the Israeli-headquartered global generics and specialty medicines group. Through its Canadian arm, Teva sells generic prescription pharmaceuticals, over-the-counter products and selected specialty medicines to pharmacies, hospitals, wholesalers and other healthcare customers across Canada. The Canadian business is part of Teva's broader North American commercial organization and draws on the parent company's global manufacturing and development network. Teva's Canadian presence has roots in Novopharm, a Canadian generics manufacturer that Teva acquired in the 2000s and subsequently rebranded under the Teva name. That legacy gave Teva Canada a substantial portfolio of generic molecules and a domestic commercial footprint. Today the Canadian entity operates as a sales, marketing and regulatory organization within the Teva group rather than as an independently listed company. As a subsidiary, Teva Canada does not publish separate financial statements; its results are consolidated into Teva Pharmaceutical Industries' global reporting. Its strategic role is to maintain and grow Teva's share of the Canadian generic drug market, launch new generic and biosimilar-type products as patents expire, and support the parent's specialty portfolio in Canada. The brand is positioned as a high-volume, cost-effective supplier of everyday medicines, competing with other global generics groups and Canadian generic manufacturers. Note: the supplied evidence snippets concern unrelated art-world subjects (Towner gallery and Blythe dolls) and contain no information about Teva Canada. This dossier therefore relies on well-established public facts about Teva and its Canadian operations; specific figures, dates and personnel are omitted where not verifiable.

Teva Canada's history is tied to the consolidation of the Canadian generic drug industry and to Teva Pharmaceutical Industries' expansion into North America. Teva, founded in Israel in 1901, grew into one of the world's largest generic pharmaceutical companies through a long series of acquisitions. Its Canadian footprint was substantially built through the acquisition of Novopharm, a Canadian generics manufacturer with a long history in the domestic market. Following the acquisition, the Canadian operations were integrated into Teva's global generics platform and eventually marketed under the Teva Canada name. The Canadian business operates within Teva's North American commercial structure, which coordinates sales, marketing, regulatory affairs and supply for the United States and Canada. Teva Canada's portfolio spans a broad range of generic molecules across therapeutic areas, supplied to retail pharmacies, hospitals and wholesalers. The company also participates in Canadian public and private drug reimbursement programs, where generic substitution policies make cost-effective generics central to the healthcare system. Over time, Teva's global strategy has shifted toward specialty medicines and biosimilars alongside its core generics business, and the Canadian subsidiary participates in bringing relevant products to the Canadian market. As a subsidiary, Teva Canada does not have a separate listing or independent corporate history beyond its role within the Teva group; its milestones are those of the parent's Canadian operations. Specific dates for the Novopharm acquisition and subsequent rebranding are not included here because they could not be verified against the supplied evidence.

• 1901

  Teva Pharmaceutical Industries founded in Israel

• Teva acquires Canadian generics manufacturer Novopharm, building its Canadian footprint

• Canadian operations marketed under the Teva Canada name

Cost-effective, high-volume supplier of generic and specialty medicines within the Canadian healthcare market, backed by a global generics leader.

• Generic prescription medicines

• Over-the-counter medicines

• Specialty pharmaceuticals

• Biosimilars

• 2026

  Teva Canada recalls two lots of Teva-Pregabalin 150 mg capsules due to sertraline cross-contamination

  Teva Canada Ltd. recalled two lots of Teva-Pregabalin 150 mg capsules (DIN 02361205, lots 100070495 and 100068913, expiry July 31, 2027) after routine testing identified that some capsules may be contaminated with the drug sertraline. Patients with a hypersensitivity or allergy to sertraline could experience side effects or a serious allergic reaction, including anaphylaxis. Health Canada is monitoring the company's recall and implementation of corrective and preventive actions.

  Source

Read more

1. 1Teva Pharmaceutical Industriestevapharm.com
2. 2Teva Canadatevacanada.com
3. 3Teva Canada recalls two lots of Teva-Pregabalin 150 mg capsules due to sertraline cross-contaminationleaderpost.com